Drug Trial Radar · NCT04855292
A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 1, 2021
Primary completion
Dec 1, 2022
Study completion Jan 1, 2023
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes
Conditions
- Diabetes
Interventions
TG103 injectionDrug
TG103 injection, SC, once weekly
PlaceboDrug
Placebo control, SC, once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability assessed by incidence and severity of adverse eventsTime frame: Up to 99 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gao Huanhuan
Beijingcun, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.